Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript

Compugen Ltd. (CGEN) reported Q2 2025 results, noting a net loss of $7.3 million on $1.3 million revenue, but highlighted a solid $93.9 million cash position with runway into 2027. The company announced a leadership transition, with CEO Anat Cohen-Dayag becoming Executive Chair and Eran Ophir taking the CEO role, aiming to strengthen strategic execution. Operationally, Compugen advanced its pipeline, initiating patient dosing in the COM701 MAIA-ovarian trial for platinum-sensitive ovarian cancer with interim data expected H2 2026. Partner AstraZeneca continues to broadly develop rilvegostomig, with new data anticipated at ESMO and a potential peak revenue exceeding $5 billion, offering substantial future milestones and royalties to Compugen, underscoring the value of their validated Unigen platform and differentiated immuno-oncology approach.

Analysis

Compugen's Q2 2025 results reflect its status as a clinical-stage biotech, with a net loss of $7.3 million on $1.3 million in revenue, a wider loss than the $2.1 million reported in the prior year's quarter. However, the company maintains a solid financial position with a cash balance of $93.9 million, providing a runway into 2027, which is sufficient to fund operations through key clinical milestones. A significant leadership transition is underway, with CEO Anat Cohen-Dayag moving to an Executive Chair role focused on strategy and CSO Eran Ophir ascending to CEO, signaling a continued emphasis on science-led execution. Operationally, Compugen has advanced its lead asset, COM701, by dosing the first patient in the MAIA-ovarian trial for platinum-sensitive ovarian cancer, with a defined clinical success metric of a three-month improvement in progression-free survival and an interim data catalyst expected in the second half of 2026. The company's value proposition is substantially de-risked and enhanced by its major partnerships. The collaboration with AstraZeneca on rilvegostomig (derived from Compugen's COM902) is particularly notable, given AstraZeneca's commitment with ten Phase III trials, its estimate of over $5 billion in non-risk-adjusted peak revenues, and Compugen's eligibility for up to $170 million in remaining milestones and mid-single-digit royalties. Upcoming presentations at ESMO on rilvegostomig and a pooled analysis of COM701 serve as near-term informational events for the market.

Key Decisions for Investors

• Investors should monitor key clinical catalysts, primarily the interim analysis for the COM701 trial in H2 2026 and, more immediately, data from partner AstraZeneca's rilvegostomig program at the upcoming ESMO conference, as positive results could significantly de-risk the pipeline.
• Given the company's $93.9 million cash position provides a runway into 2027, the primary financial consideration is the execution of clinical programs within this timeframe, while recognizing that potential milestone payments from AstraZeneca or Gilead could provide non-dilutive capital extensions.
• A significant portion of Compugen's valuation is linked to the success of its partners' programs; therefore, positions in CGEN should be viewed as a leveraged investment in the outcome of AstraZeneca's rilvegostomig, whose success would validate Compugen's TIGIT approach and unlock substantial royalty streams.